<DOC>
	<DOCNO>NCT01124006</DOCNO>
	<brief_summary>Study show safety tolerability Intradiscal rhGDF-5 subject early lumbar disc degeneration</brief_summary>
	<brief_title>A Multicenter , Randomized , Double-blind , Placebo Controlled , Clinical Trial Evaluate Safety , Tolerability Preliminary Effectiveness 2 Doses Intradiscal rhGDF-5 ( Single Administration ) Treatment Early Stage Lumbar Disc Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>1 . Persistent low back pain least 3 month nonsurgical therapy one suspect symptomatic lumbar level ( L3/L4 L5/S1 ) confirm use standardize provocative discography protocol . The required discography protocol provide sponsor . Subjects multilevel disease must provocative discogram confirm 1 level symptomatic least 2 week prior administration . Historical provocative discograms may use screening purpose , expiry 12 calendar month date perform . If study treatment perform within 12 calendar month , new discogram require . 2 . Oswestry Disability Index ( ODI ) low back pain 30 great 3 . Low Back Pain score great equal 4 cm measure Visual Analog Scale ( VAS ) Visit 1 Baseline 1 . Persons unable discogram , CT , MRI 2 . Abnormal neurological exam baseline ( e.g. , chronic radiculopathy ) 3 . Active radicular pain due anatomical compression stenosis disc herniation ( radicular pain define pain knee ) 4 . Extravasation contrast agent discogram , epidural space ( include leakage contrast agent along needle track leakage outer annular ring posterior longitudinal ligament vicinity ) 5 . Suspected symptomatic facet joint and/or severe facet joint degeneration index level adjacent segment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>